Last reviewed · How we verify
ASF 1096 0.5 % cream applied twice daily — Competitive Intelligence Brief
phase 2
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
ASF 1096 0.5 % cream applied twice daily (ASF 1096 0.5 % cream applied twice daily) — Astion Pharma A/S. ASF 1096 is a topical cream formulation with an unknown mechanism of action in Phase 2 development by Astion Pharma A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ASF 1096 0.5 % cream applied twice daily TARGET | ASF 1096 0.5 % cream applied twice daily | Astion Pharma A/S | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ASF 1096 0.5 % cream applied twice daily CI watch — RSS
- ASF 1096 0.5 % cream applied twice daily CI watch — Atom
- ASF 1096 0.5 % cream applied twice daily CI watch — JSON
- ASF 1096 0.5 % cream applied twice daily alone — RSS
Cite this brief
Drug Landscape (2026). ASF 1096 0.5 % cream applied twice daily — Competitive Intelligence Brief. https://druglandscape.com/ci/asf-1096-0-5-cream-applied-twice-daily. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab